Torrent Pharma posts Rs 287 crore net profit in Q4

AHMEDABAD: Homegrown pharma major, Torrent Pharmaceuticals Limited posted Rs 287 crore in profit for the fourth quarter of the fiscal year 2022-23, the company said on Tuesday in its stock exchange filing. Torrent Pharma posted a net loss of Rs 118 crore during the corresponding period.
During the full fiscal year 2022-23, its net profit reached Rs 1,245 crore, up 60% against Rs 777 crore in the previous fiscal.
The board of the pharma company also recommended a dividend of Rs 8 per share, subject to the shareholders’ approval. The company's revenue rose to Rs 2,491 crore for the fourth quarter compared to Rs 2,131 crore in the year-ago period, Torrent Pharma said in a statement.
The flagship company of the Torrent Group, Torrent Pharma, is among the Top 5 in the therapeutics segments of Cardiovascular (CV), Gastro Intestinal (GI), Central Nervous System (CNS), Vitamins Minerals Nutritionals (VMN), and Cosmo-Dermatology and is ranked 6th in the Indian pharmaceuticals industry.
The company’s share price closed on the BSE at Rs 1,717.15 a piece, up by 0.69% against the previous close of Rs 1,705.40.